ondansetron has been researched along with Marijuana Abuse in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Marijuana Abuse: Use of marijuana associated with abnormal psychological, social, and or occupational functioning.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 9.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 5.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruberto, AJ | 1 |
| Sivilotti, MLA | 1 |
| Forrester, S | 1 |
| Hall, AK | 1 |
| Crawford, FM | 1 |
| Day, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome[NCT05244460] | Phase 3 | 45 participants (Anticipated) | Interventional | 2021-12-02 | Recruiting | ||
| Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial[NCT03056482] | Phase 4 | 33 participants (Actual) | Interventional | 2017-05-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ondansetron and Marijuana Abuse
| Article | Year |
|---|---|
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |